- Title
- The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes
- Creator
- Kerridge, R.; Whyte, I.; Prior, F.; Luu, J.; Story, D. A.
- Relation
- Anaesthesia and Intensive Care Vol. 46, Issue 2, p. 155-158
- Publisher Link
- http://dx.doi.org/10.1177/0310057X1804600202
- Publisher
- Sage Publications
- Resource Type
- journal article
- Date
- 2018
- Description
- Among the eight classes of drugs available to control blood sugar in patients with type 2 diabetes, the newest class is the sodium-glucose cotransporter-2 (SGLT2) inhibitors, or 'gliflozins', which includes canagliflozin, dapagliflozin and empagliflozin. These recently introduced medications are widely predicted to become commonly used in type 2 diabetes. There are now concerns of some common, and some rare but serious, hazards that may be associated with these medications in the perioperative setting.
- Subject
- type 2 diabetes; gliflozins; sodium-glucose cotransporter-2 (SGLT2) inhibitors; disease control; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1466799
- Identifier
- uon:47663
- Identifier
- ISSN:0310-057X
- Language
- eng
- Reviewed
- Hits: 1197
- Visitors: 1196
- Downloads: 0